BlinkLab

Quarterly Activities Report and Appendix 4C for the Period Ended 31 December 2024

BlinkLab Limited (ASX:BB1) (“BlinkLab”, or the “Company”) an innovative digital healthcare company leveraging smartphones, computer vision, Artificial Intelligence (“AI”), and Machine Learning (“ML”) to diagnose neurodevelopmental conditions such as autism and ADHD, is pleased to release its Appendix 4C and Quarterly Activity Report for the period ended 31 December 2024 (the “Quarter”).


Highlights

  • BlinkLab initiated its FDA registrational study, which aims to revolutionise the diagnostics and care for autism, making it more accessible and reliable.
    • The initial phase will recruit up to 100 participants (children aged between 2-11 years old), with the main study recruiting up to 1,000 subjects.
    • Four clinical sites have been selected, with six additional sites to be added; the sites are spread across the US to ensure diversity of the population.
    • Final results are expected by the end of CY 2025 and will be used for the 510(k) Food and Drug Administration (“FDA”) approval.
  • BlinkLab received positive feedback from a Pre-Submission meeting with the US Federal Drug Administration (“FDA”) regarding the regulatory pathway for BlinkLab Dx 1 diagnostic app.
  • Final results from the pivotal autism study (announced in November of 2024) bolster confidence that BlinkLab Dx 1 will surpass the accuracy parameters that are required for regulatory approval in the upcoming FDA registration trial.
  • BlinkLab and Monash University have partnered on the large-scale Monash Autism-ADHD Genetics and Neurodevelopment (“MAGNET”) study, which aims to conduct deep phenotyping in children on the autism spectrum, with ADHD, or both. The study will also work towards further improvements to BlinkLab’s Machine Learning (“ML”) algorithm to better distinguish between autism- and ADHD-specific clinical features.
  • As at 31 December 2024, the Company had a cash balance of A$4.4 million.

Following the positive outcome from the recent FDA pre-submission meeting, as well as positive final data from the pivotal preliminary study (ASX Announcement 19 November 2024), BlinkLab is confident in the success of its registrational study, as well as the subsequent 510(k) regulatory approval for our first diagnostic tool for autism, called “Blinklab Dx 1”.

US FDA Registrational Study in Autism Now Underway

The FDA registrational study program will consist of a pilot study, followed by the primary study. The pilot study will recruit up to 100 participants (children aged between 2-11 years) and will continue into a registrational study, which will be conducted with up to 1,000 subjects across ten clinical sites in the US. The pilot study will be used to train the investigators and personnel at clinical sites, as well as to test the procedures of subject screening and data collection. These steps are part of BlinkLab’s considered strategy for mitigating risk leading up to the main FDA study and are aimed at ensuring the highest quality of data and diagnostic accuracy of the BlinkLab tests.


Click here for the full ASX Release

This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BB1:AU
The Conversation (0)
Robotic hand and human hand reaching out to touch glowing brain.

ASX AI Stocks: 5 Biggest Companies in 2025

Artificial intelligence (AI) continues to evolve and advance rapidly, becoming increasingly integrated in the automation of everyday life and a focal point of growth in the technology sector.

According to a September 2023 report from IDC on worldwide AI spending, Australia is leading the Asia-Pacific region in spending on AI solutions along with Korea and India; the three countries are also leading when it comes to AI adoption in the area. Spending in the region, excluding Japan and China, is expected to reach US$28.2 billion by 2027.

Although the AI market is relatively small in Australia, it’s growing. To help investors understand the options available, the Investing News Network used TradingView's stock screener to find the top AI stocks on ASX by market cap. All ASX AI stocks data was current as of July 11, 2025. Companies whose businesses are focused mainly on AI were considered.

Keep reading...Show less
Microchip with American flag design on a circuit board.

White House Unveils 90 Point AI Strategy

The White House on Wednesday (July 23) released a sweeping national strategy for artificial intelligence (AI), outlining over 90 federal actions designed to strengthen America’s position as the global leader in AI development.

The document fulfills a mandate laid out in President Donald Trump’s January 23 executive order, which called for the removal of what the administration described as “barriers to American leadership” in the field.

Titled “Winning the AI Race: America’s AI Action Plan,” the plan sets priorities across three core pillars: accelerating innovation, building domestic infrastructure and leading on global AI diplomacy and security.

Keep reading...Show less
Syntheia (CSE:SYAI)

Syntheia Announces Private Placement

Syntheia Corp. (CSE: SYAI)(CSE: SYAI) (syntheia.ai) (the "Company"), is pleased to announce that it intends to complete a non-brokered private placement financing for gross proceeds of up to $4,200,000 through the issuance of up to 35,000,000 units (each, a "Unit") at a price of $0.12 per Unit (the "Offering").

Each Unit will be comprised of one common share in the capital of the Company (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant is exercisable to acquire one Common Share at a price of $0.16 until the date that is five years from the closing of the Offering (the "Expiry Date"), subject to an accelerated expiry in the event the volume weighted average trading price of the Common Shares exceeds $0.20 for 20 consecutive trading days, the Company may, within 10 business days of the occurrence of such event, deliver a notice to the holders of the Warrants accelerating their Expiry Date to a date that is not less than 30 days following the date of such notice and the issuance of a press release by the Company announcing the acceleration notice (the "Accelerated Exercise Period"). Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.

Keep reading...Show less
Digital circuit overlay on US dollar bills, representing technology and finance.

Tech Giants Escalate AI Spending in Race to Stay Competitive

The artificial intelligence (AI) arms race is entering a new phase as major industry players ramp up spending.

In the span of just a few weeks, the world’s biggest tech firms have unveiled a flurry of moves aimed at shoring up their positions, ranging from massive chip and data center deals to fresh funding rounds.

Keep reading...Show less
NVIDIA logo with chip-making machine.

Tech 5: TSMC, ASML Release Latest Results, NVIDIA to Resume Sales to China

Investors honed in on tech stocks as Q2 earnings season kicked off on Monday (July 14).

Some experts believe the rallying market is showing signs of frothiness.

Apollo Global Management (NYSE:APO) Chief Economist Torsten Sløk highlighted concerns about overvaluation mid-week, comparing the current tech craze to the dotcom bubble of the 1990s.

Keep reading...Show less
AI text over a vibrant, futuristic, technological background with dynamic lines and symbols.

AI Market Update: Q2 2025 in Review

Q2 confirmed that the artificial intelligence (AI) boom is entering a new phase in the physical world.

As the industry evolves, attention is being directed to strengthening underlying infrastructure while advancing areas like embodied AI, a subsector that MarketsandMarkets projects will grow at a CAGR of 39 percent globally by 2030.

Also during Q2, a geopolitical tech rivalry exacerbated shifting macroeconomic conditions.

Keep reading...Show less

Latest Press Releases

Related News

×